QL1706
- Generic Name
- QL1706
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2024-05-21
- Target Recruit Count
- 39
- Registration Number
- NCT05490719
- Locations
- 🇨🇳
Tianjin cancer hospital, Tianjin, Tianjin, China
QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 498
- Registration Number
- NCT05446883
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Liaoning Cancer Hospital, Shenyang, Liaoning, China
A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05329025
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05309629
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05179317
- Locations
- 🇨🇳
Shandong Cancer Hospital, Jinan, Shangdong, China
🇨🇳Liaoning Cancer Hospital, Shenyang, Liaoning, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath